ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1568

Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study

Barkha Amlani1, Umang Barvalia2, Ghada Metwally Ahmed Elsayed3, Jeffrey P. Kanne4, Zhanhai Li5 and Sara S. McCoy6, 1Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2Pulmonary And Critical Care, university of wisconsin Hospital and clinics, Madison, WI, 3Rheumatology, University of Wisconsin Hospital and clinics, Madison, WI, 4Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 5University of Wisconsin School of Medicine and Public Health, Madison, WI, 6Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: azathioprine, interstitial lung disease and mycophenolate mofetil, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, October 22, 2018

Session Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a common extraglandular manifestation of Sjögren’s syndrome (SS).  There is a paucity of literature on the management of SS-ILD.  The aim of this retrospective cohort study is to assess the efficacy of immunosuppressive therapy in the treatment of adult patients with SS-ILD.

Methods: A retrospective electronic health record search using codes for ILD and SS was performed for patients seen between 2000-2017at an academic medical center.  Records were reviewed to include adults meeting the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for SS and to exclude those with other connective tissue diseases.  ILD was confirmed by characteristic CT pattern or histopathology findings. Sociodemographic, clinical, and pulmonary function test (PFT) data were abstracted for patients with and without azathioprine, mycophenolate, and rituximab treatment and followed longitudinally from the date of ILD diagnosis.  PFT values were anchored (T0) on time of treatment start.  Linear mixed-effects modeling and paired t-tests were used to analyze changes in diffusion capacity for carbon monoxide (DLCO) and forced vital capacity (FVC) before and after treatment initiation.

Results: We identified 19 subjects who had SS-ILD, of whom 89% were female, with ages ranging from 37-84 years at the time of ILD diagnosis.  Seven patients were treated with azathioprine, seven patients were treated with mycophenolate, and six patients were treated with rituximab.  Five patients were not treated with immunosuppressive therapy and five patients were treated with more than one agent.   Within the azathioprine group, paired t-test showed a significant improvement in FVC% after treatment was initiated (p=0.01) with mixed model effect similarly showing improvement although with a non-significant change in slope (p=0.22) (Figure 1). A trend toward improvement in slope was also seen in DLCO% after treatment with azathioprine (p=0.16).  Similarly, among those treated with mycophenolate, there was a trend toward improvement in slopes of both FVC% and DLCO% (FVC% p=0.4, DLCO% p=0.45), although these did not reach statistical significance (Figure 2).  Among those patients treated with rituximab, there was a post-treatment decline in FVC% and DLCO%, although only three patients had PFTs measured before and after treatment.

Conclusion: Azathioprine appears to improve PFTs of SS-ILD patients and a similar non-significant trend is seen after mycophenolate treatment.  Further prospective studies are needed to further evaluate these findings.


Disclosure: B. Amlani, None; U. Barvalia, None; G. M. Ahmed Elsayed, None; J. P. Kanne, None; Z. Li, None; S. S. McCoy, None.

To cite this abstract in AMA style:

Amlani B, Barvalia U, Ahmed Elsayed GM, Kanne JP, Li Z, McCoy SS. Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/azathioprine-and-mycophenolate-for-management-of-sjogrens-syndrome-related-interstitial-lung-disease-a-retrospective-cohort-study/. Accessed January 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/azathioprine-and-mycophenolate-for-management-of-sjogrens-syndrome-related-interstitial-lung-disease-a-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.